C: \NRPortbl\DCC\DAR\489270_l.DOC-17 12/2012 Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions kits and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs. Hexahydrocolupulone _-^-7.1 0.57 Spent Hops : 1.11 Beta-Acids 1 .24 Alpha Acids sw ____ _ -' 1 1.45 -_- I _ _ ii _ Xanthohumol rrImm mm - 1.46 Hexahydroisoalpha acids Ir:".E 2 Tetrahydroisoalpha acids I m z m4 : 1.79 __I 'i__ f_ W Rho-isoaipha acids 2.25 Isoaipha acids -____ ____ 2.45 Indomethacin m_ _ ________ . 1.33 Troglitazone - --1 1.43 Solvent Control a 1.00 0.00 0.50 1.00 1.50 2.00 2.50 3.00 Relative Nonpolar Lipid Content WO 2007/070355 PCT/US2006/046770 Hexahydrocolupulone kv e L7.I 10.57 Spent Hops m re me m:I 1.11 Beta-Acids 1 m Thw's = - .24 Alpha Acids m n a m 1.45 Xanthohumol r a m a i -1 1.46 Hexahydroisoalpha acids amme-r sa.a : - 1. 2 Tetrahydroisoalpha acids a mae r1- 1.79 Rho-isoalpha acids a -:" _________ : 2.25 Isoalpha acids a ____________n: 4 2.45 Indomethacin m22 mm5mfer : 1.33 Troglitazone 77 .7 77m75777:77 i 1.43 Solvent Control mi - n ~ 1.00 0.00 0.50 1.00 1.50 2.00 2.50 3.00 Relative Nonpolar Lipid Content Fig. 18

暂无附图